|
Market Closed -
Other stock markets
|
Pre-market 08:00:00 pm | |||
| 130.04 USD | -1.04% |
|
128.50 | -1.18% |
| Jul. 14 | Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo | RE |
| Jul. 08 | Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says | MT |
| Market Cap | 163B 143B 132B 122B 229B 15,693B 234B 1,576B 617B 7,669B 613B 599B 26,464B | P/E 2026 * |
-47.3x | P/E 2027 * | 16.7x |
|---|---|---|---|---|---|
| Enterprise Value | 173B 151B 140B 129B 243B 16,603B 248B 1,667B 653B 8,113B 648B 634B 27,999B | EV / Sales 2026 * |
5.67x | EV / Sales 2027 * | 5.04x |
| Free-Float |
99.88% | Yield 2026 * |
2.47% | Yield 2027 * | 2.56% |
Last Transcript: Gilead Sciences, Inc.
| 1 day | -1.04% | ||
| 1 week | -4.63% | ||
| Current month | +2.93% | ||
| 1 month | +3.54% | ||
| 3 months | -7.41% | ||
| 6 months | +4.81% | ||
| Current year | +5.95% |
| 1 week | 127.94 |  | 136.06 |
| 1 month | 122.43 | | 137.7 |
| Current year | 116.88 | | 157.29 |
| 1 year | 107.75 | | 157.29 |
| 3 years | 62.07 | | 157.29 |
| 5 years | 57.16 | | 157.29 |
| 10 years | 56.56 | | 157.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 2019-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 2019-10-31 |
Keeley Wettan
CMP | Compliance Officer | - | 2025-12-17 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 2016-08-18 |
| Director/Board Member | 73 | 2017-12-31 | |
Harish Manwani
BRD | Director/Board Member | 72 | 2018-05-08 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| Jun. 30 | Sell | Chief Executive Officer | -15,000 | 0.0012% | ||
| Jun. 14 | Sell | Executive/Senior Manager | -3,000 | 0.0002% | ||
| Jun. 14 | Sell | Chief Financial Officer | -3,000 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.04% | -4.63% | +16.01% | +68.47% | 163B | |
| -2.48% | -6.72% | +44.19% | +156.43% | 1,054B | |
| -1.52% | -5.01% | +61.87% | +58.79% | 621B | |
| -1.30% | -3.88% | +27.81% | +79.97% | 438B | |
| -1.12% | -3.68% | +26.89% | +20.58% | 325B | |
| -1.73% | -3.45% | +26.95% | +44.09% | 281B | |
| -1.95% | -13.92% | +15.96% | +19.76% | 262B | |
| -1.45% | -2.37% | -27.87% | -39.87% | 219B | |
| -1.44% | -3.49% | +19.60% | +56.20% | 195B | |
| -0.94% | +0.75% | -4.34% | -33.23% | 140B | |
| Average | -0.82% | -1.21% | +20.71% | +43.12% | 369.57B | |
| Weighted average by Cap. | -0.40% | -1.50% | +31.75% | +72.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.46B 26.68B 24.66B 22.75B 42.83B 2,930B 43.69B 294B 115B 1,432B 114B 112B 4,942B | 32.38B 28.36B 26.21B 24.18B 45.53B 3,115B 46.44B 313B 122B 1,522B 122B 119B 5,253B |
| Net income | -3.39B -2.97B -2.74B -2.53B -4.77B -326B -4.86B -32.75B -12.83B -159B -12.74B -12.45B -550B | 9.76B 8.55B 7.9B 7.29B 13.72B 939B 14B 94.29B 36.93B 459B 36.66B 35.85B 1,584B |
| Net Debt | 9.46B 8.28B 7.66B 7.07B 13.3B 910B 13.57B 91.37B 35.79B 445B 35.53B 34.75B 1,535B | -96.43M -84.44M -78.05M -72.02M -136M -9.28B -138M -931M -365M -4.53B -362M -354M -15.64B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-14 | $130.04 | -1.04% | 5,219,968 |
| 26-07-13 | $131.40 | +1.21% | 5,131,594 |
| 26-07-10 | $129.83 | -3.72% | 5,935,997 |
| 26-07-09 | $134.84 | -0.72% | 5,839,339 |
| 26-07-08 | $135.82 | -0.40% | 8,454,142 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
